Mesoblast股票飙升至52周高点，触及12.19美元
在一场令人瞩目的市场韧性展示中，Mesoblast Ltd股票已飙升至52周高点，达到12.19美元的价格水平。该股票市值为13.7亿美元，贝塔系数为2.34，显示出显著的波动性。根据 InvestingPro 数据，分析师的目标价格范围从11美元到18美元不等，暗示可能存在上涨空间。这一重要里程碑凸显了这家生物制药公司强劲增长的时期，其股票价值年初至今已飙升了惊人的432.73%。投资者对Mes ...
Mesoblast’s Revascor Shows Promise in Heart Failure Treatment
Mesoblast Limited (AU:MSB) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - ...
Mesoblast’s Revascor improves survival in heart failure patients
Mesoblast Limited announced a key publication in the November 2024 online issue of the prestigious peer-reviewed European Journal of Heart Failure, which re ...
pharmaphorum1 年
Mesoblast poised to file cell therapy for GVHD in US
Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA. The ‘rolling ...
ETF Daily News11 天
Mesoblast (NASDAQ:MESO) Shares Gap Down – Here’s Why
Mesoblast Limited (NASDAQ:MESO – Get Free Report)’s stock price gapped down prior to trading on Thursday .The stock had previously closed at $10.33, but opened at $10.00. Mesoblast shares last ...
Nasdaq20 天
Mesoblast Issues 2 Million Warrants for Strategic Flexibility
Mesoblast (MESO) has released an update. Mesoblast Limited has issued 2 million unquoted warrants as part of a US$50 million convertible note facility, which the company can utilize following FDA ...
Morningstar7 天
Mesoblast Ltd ADR MESO
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nasdaq27 天
Mesoblast Issues Warrants in $50 Million Agreement
Mesoblast Limited (AU:MSB) has released an update. Mesoblast Limited has announced the issuance of 2 million warrants to its largest shareholder, Dr. Gregory George, as part of a convertible note ...
CNN11 个月
Mesoblast Limited Sponsored ADR
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target ...
ASX 200 ends the day down by 0.38 per cent on Wednesday
The ASX 200 ended the day down by 0.38 per cent on Wednesday. The market’s top performers were Lynas, Zip and Champion Iron.
Wall Street Journal12 年
Mesoblast Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Wall Street Journal4 年
Mesoblast Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...